PCOS and the endocannabinoid system: ovaries, insulin and cannabinoids

PCOS is more than cysts in the ovaries

Polycystic ovary syndrome (PCOS) is a heterogeneous hormonal and metabolic condition. Depending on the individual, it may involve irregular ovulation, unpredictable periods, elevated androgens, acne, excess hair growth, difficulty conceiving and increased metabolic risk. A person can have PCOS without a classic ultrasound appearance of polycystic ovaries. The condition involves interactions among the brain, ovaries, insulin signaling, adipose tissue and other organs, not only ovarian anatomy.

Why insulin resistance is important

Many people with PCOS have some degree of insulin resistance. Higher insulin levels can interact with the ovaries and androgen production, reinforcing endocrine and metabolic difficulties. But people with PCOS differ in body composition, insulin function and reproductive goals. This heterogeneity is central to interpreting research and to individual management.

What the endocannabinoid system does

The endocannabinoid system (ECS) helps regulate neural signaling and participates in appetite, energy balance, lipid metabolism and other processes. CB1 receptors occur in the brain and metabolic tissues; CB2 signaling is studied in immune biology. Researchers have asked whether altered endocannabinoid activity could participate in the metabolic and reproductive features of PCOS. Asking that question does not establish a cannabis treatment.

A small human study found an association

One case-control investigation compared 20 women with PCOS and 20 controls matched for age and body-mass index. It reported higher circulating anandamide and 2-AG and changes in cannabinoid receptor expression in the PCOS group. Some measures were associated with glucose and insulin responses during an oral glucose tolerance test. These findings support further study of the ECS and insulin resistance, but an observational study of 40 people cannot show which process causes the other.

Not every study has found the same pattern

Other work has reported different or more subgroup-specific findings for anandamide. Studies of the endometrium have examined changes in FAAH, the enzyme that breaks down anandamide, and changes observed alongside hormonal or metabolic treatment. Differences in fat distribution, hormone profiles, assay methods and study populations may partly explain apparent disagreements. These are hypotheses, not established PCOS subtypes diagnosed through ECS testing.

Does the ECS have a role in fertility?

Endocannabinoid signaling is studied in follicle development, ovulation, implantation and early reproductive events. Precise local timing and concentration may matter. An association between PCOS and altered ECS markers cannot prove that those changes cause infertility, or that adding THC or CBD could correct them. Naturally occurring anandamide is produced and cleared in carefully regulated contexts; externally administered cannabinoids have different pharmacological effects.

Why activating CB1 might not be helpful

The fact that a receptor is linked to a condition does not mean stimulating it will improve that condition. If excessive CB1 activity contributes to metabolic dysregulation in some circumstances, additional activation could theoretically be unhelpful. Research into receptor modulation, peripheral targets and PPAR-related pathways is distinct from advising patients to use cannabis. There is no convincing clinical trial evidence that THC or CBD treats PCOS itself, restores ovulation or improves fertility.

Care should follow established PCOS guidance

Clinical management considers menstrual regularity, metabolic health, mental health, fertility goals and individualized evidence-based options. Weight and lifestyle support, treatment of hyperandrogenic symptoms, metabolic management and fertility treatment may be relevant depending on the patient. Cannabis-related changes in appetite, mood and medication interactions can complicate decisions, especially when trying to conceive. The 2023 international evidence-based PCOS guideline does not establish cannabis as a standard PCOS therapy.

Key conclusion

Human and experimental research makes the ECS an intriguing research target in PCOS, particularly in relation to insulin resistance and reproductive signaling. Results are not uniform, causality is unresolved, and no clinical benefit from THC or CBD for treating PCOS has been established. Understanding a biological pathway is not the same thing as having a safe or effective treatment.

Original references and Hebrew article

This article is an editorial adaptation of the Hebrew original.

1. Juan CC, et al. Endocannabinoid system activation may be associated with insulin resistance in women with polycystic ovary syndrome. Fertility and Sterility. Find publication ↗
2. Cui N, et al. Restored Plasma Anandamide and Endometrial FAAH in Women With PCOS by Diane-35 and Metformin. Find publication ↗
3. Anandamide is associated with waist-to-hip ratio but not BMI in women with PCOS. Find publication ↗
4. Cannabinoids and PPAR Ligands: The Future in Treatment of PCOS Women with Obesity and Reduced Fertility. Find publication ↗
5. 2023 international evidence-based PCOS guideline Find publication ↗

Read original Hebrew article ↗

Educational information only. This page is not a diagnosis or a treatment recommendation. Do not alter prescribed care without consulting the treating clinician, especially in neurological illness, fertility planning or pregnancy.